Symbols / GLUE Stock $19.20 -2.98% Monte Rosa Therapeutics, Inc.

Healthcare • Biotechnology • United States • NMS
GLUE (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Biotechnology
CEO Dr. Markus Warmuth M.D.
Exch · Country NMS · United States
Market Cap 1.54B
Enterprise Value 1.25B
Income -38.63M
Sales 123.67M
FCF (ttm) -129.08M
Book/sh 3.56
Cash/sh 4.71
Employees 150
Insider 10d —
IPO Jun 24, 2021
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 0.00%
P/E 49.25
Forward P/E -11.29
PEG —
P/S 12.42
P/B 5.40
P/C —
EV/EBITDA -27.17
EV/Sales 10.07
Quick Ratio 6.05
Current Ratio 6.12
Debt/Eq 16.82
LT Debt/Eq —
EPS (ttm) -0.46
EPS next Y -1.70
EPS Growth —
Revenue Growth -95.40%
EPS Gr Q/Q —
Rev Gr Q/Q —
Earnings (next) 2026-05-07
Earnings (prior) 2026-03-17
ROA -7.64%
ROE -16.94%
ROIC —
Gross Margin -8.11%
Oper. Margin -17.88%
Profit Margin -31.23%
Shs Outstand 80.02M
Shs Float 57.20M
Insider Own 0.74%
Instit Own 88.59%
Short Float 24.41%
Short Ratio 12.23
Short Interest 15.84M
52W High 25.77
vs 52W High -25.49%
52W Low 3.51
vs 52W Low 447.01%
Beta 1.64
Impl. Vol. 1.50%
Rel Volume 0.23
Avg Volume 1.10M
Volume 252.64K
Target (mean) $32.17
Tgt Median $30.00
Tgt Low $29.00
Tgt High $37.00
# Analysts 6
Recom Strong_buy
Prev Close $19.79
Price $19.20
Change -2.98%
About

Monte Rosa Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. The company develops orally bioavailable molecular glue degraders (MGDs), such as MRT-2359 for the treatment of MYC-driven tumors; MRT-6160 for the treatment of neurologic and systemic autoimmune and inflammatory diseases; and MRT-8102 for the treatment of inflammatory diseases driven by IL-1a, IL-1ß and IL-18, as well as damage-associated molecular patterns. In addition, it develops CDK2 to treat multiple cancers, including ovarian, endometrial, gastric and breast. Further, its pipeline includes programs in immunology and inflammation indications, oncology, cardiovascular, metabolic, and genetic diseases. The company also develops QuEEN, a discovery engine, to enable its target-centric MGD discovery and development approach and its rational design of MGD product candidates. It has a strategic collaboration and licensing agreement with F. Hoffmann-La Roche Ltd.; and Novartis. The company was incorporated in 2019 and is headquartered in Boston, Massachusetts.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$32.17
Mean price target
2. Current target
$19.20
Latest analyst target
3. DCF / Fair value
$-29.04
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$19.20
Low
$29.00
High
$37.00
Mean
$32.17

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2026-03-18 main Guggenheim Buy → Buy $30
2026-03-18 main Wells Fargo Overweight → Overweight $29
2026-01-14 reit Piper Sandler Overweight → Overweight $37
2026-01-08 main Wells Fargo Overweight → Overweight $30
2026-01-08 main Guggenheim Buy → Buy $34
2025-12-16 up Wells Fargo Equal-Weight → Overweight $22
2025-11-07 main Wells Fargo Equal-Weight → Equal-Weight $13
2025-03-21 main Wells Fargo Equal-Weight → Equal-Weight $10
2025-03-21 main Wedbush Outperform → Outperform $17
2025-03-12 init LifeSci Capital — → Outperform $19
2024-12-19 down Wells Fargo Overweight → Equal-Weight $11
2024-09-12 reit Wedbush Outperform → Outperform $11
2024-08-12 main Wells Fargo Overweight → Overweight $17
2024-06-28 reit Piper Sandler Overweight → Overweight $16
2024-05-22 reit Wedbush Outperform → Outperform $11
2024-02-15 init Wedbush — → Outperform $11
2023-10-19 main JP Morgan Overweight → Overweight $11
2023-08-11 reit Credit Suisse Neutral → Neutral $11
2023-05-12 reit Credit Suisse Neutral → Neutral $11
2023-03-17 main Credit Suisse — → Neutral $11
News
RSS: Latest GLUE news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2026-04-14 WARMUTH MARKUS M.D. Chief Executive Officer — 8,000 $17.64 $141,125
2026-04-09 NICKSON PHILIP Officer — 5,845 $17.69 $103,413
2026-04-06 BOWEN MATTHEW Officer — 4,300 $0.00 $0
2026-03-04 DUNN EDMUND Officer — 139 $17.96 $2,496
2026-03-02 WARMUTH MARKUS M.D. Chief Executive Officer — 5,466 $17.92 $97,974
2026-03-02 DUNN EDMUND Officer — 25,700 $17.50 $464,886
2026-03-02 DUNN EDMUND Officer — 25,700 $13.41 $344,637
2026-02-23 JANKU FILIP Officer — 9,189 $19.50 $179,161
2026-01-07 WARMUTH MARKUS M.D. Chief Executive Officer — 5,466 $23.24 $128,373
2026-01-05 TOWNSON SHARON Officer — 3,155 $15.17 $47,861
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
123.67
+63.54%
75.62
0.00
0.00
Operating Revenue
123.67
+63.54%
75.62
0.00
0.00
Operating Expense
177.88
+13.49%
156.73
+9.37%
143.31
+27.52%
112.38
Research And Development
141.50
+16.40%
121.56
+9.25%
111.27
+30.81%
85.06
Selling General And Administration
36.38
+3.44%
35.17
+9.78%
32.04
+17.26%
27.32
General And Administrative Expense
36.38
+3.44%
35.17
+9.78%
32.04
+17.26%
27.32
Salaries And Wages
22.98
+3.71%
22.15
+12.75%
19.65
+27.69%
15.39
Other Gand A
13.40
+2.97%
13.02
+5.06%
12.39
+3.81%
11.94
Total Expenses
177.88
+13.49%
156.73
+9.37%
143.31
+27.52%
112.38
Operating Income
-54.21
+33.17%
-81.11
+43.40%
-143.31
-27.52%
-112.38
Total Operating Income As Reported
-54.21
+33.17%
-81.11
+43.40%
-143.31
-27.52%
-112.38
EBITDA
-45.85
+37.18%
-72.99
+46.76%
-137.09
-26.19%
-108.64
Normalized EBITDA
-47.40
+35.44%
-73.41
+46.04%
-136.05
-25.10%
-108.76
Reconciled Depreciation
8.36
+2.89%
8.12
+30.52%
6.22
+66.14%
3.75
EBIT
-54.21
+33.17%
-81.11
+43.40%
-143.31
-27.52%
-112.38
Total Unusual Items
1.54
+270.91%
0.42
+140.12%
-1.04
-971.43%
0.12
Total Unusual Items Excluding Goodwill
1.54
+270.91%
0.42
+140.12%
-1.04
-971.43%
0.12
Special Income Charges
0.06
0.00
-100.00%
0.02
-77.98%
0.11
Net Income
-38.63
+46.87%
-72.70
+46.29%
-135.35
-24.75%
-108.50
Pretax Income
-39.72
+43.36%
-70.13
+48.06%
-135.01
-24.44%
-108.50
Net Non Operating Interest Income Expense
12.94
+22.49%
10.57
+13.20%
9.33
+147.98%
3.76
Net Interest Income
12.94
+22.49%
10.57
+13.20%
9.33
+147.98%
3.76
Interest Income Non Operating
12.94
+22.49%
10.57
+13.20%
9.33
+147.98%
3.76
Interest Income
12.94
+22.49%
10.57
+13.20%
9.33
+147.98%
3.76
Other Income Expense
1.54
+270.91%
0.42
+140.12%
-1.04
-971.43%
0.12
Other Non Operating Income Expenses
—
—
—
—
Gain On Sale Of Security
1.48
+256.73%
0.42
+139.21%
-1.06
-10710.00%
0.01
Tax Provision
-1.10
-142.68%
2.57
+660.36%
0.34
0.00
Tax Rate For Calcs
0.00
-86.67%
0.00
+0.00%
0.00
0.00
Tax Effect Of Unusual Items
0.04
-50.54%
0.09
+140.12%
-0.22
0.00
Net Income Including Noncontrolling Interests
-38.63
+46.87%
-72.70
+46.29%
-135.35
-24.75%
-108.50
Net Income From Continuing Operation Net Minority Interest
-38.63
+46.87%
-72.70
+46.29%
-135.35
-24.75%
-108.50
Net Income From Continuing And Discontinued Operation
-38.63
+46.87%
-72.70
+46.29%
-135.35
-24.75%
-108.50
Net Income Continuous Operations
-38.63
+46.87%
-72.70
+46.29%
-135.35
-24.75%
-108.50
Normalized Income
-40.13
+45.05%
-73.03
+45.72%
-134.53
-23.86%
-108.62
Net Income Common Stockholders
-38.63
+46.87%
-72.70
+46.29%
-135.35
-24.75%
-108.50
Diluted EPS
—
-1.18
+55.06%
-2.63
-14.35%
-2.30
Basic EPS
—
-1.18
+55.06%
-2.63
-14.35%
-2.30
Basic Average Shares
—
61.51
+19.67%
51.40
+8.83%
47.23
Diluted Average Shares
—
61.51
+19.67%
51.40
+8.83%
47.23
Diluted NI Availto Com Stockholders
-38.63
+46.87%
-72.70
+46.29%
-135.35
-24.75%
-108.50
Gain On Sale Of PPE
0.06
0.00
-100.00%
0.02
-77.98%
0.11
Line Item Trend 2022-12-31
Total Assets
342.39
Current Assets
275.89
Cash Cash Equivalents And Short Term Investments
262.83
Cash And Cash Equivalents
54.91
Other Short Term Investments
207.91
Receivables
7.66
Other Receivables
7.66
Prepaid Assets
—
Restricted Cash
0.96
Other Current Assets
4.44
Total Non Current Assets
66.50
Net PPE
61.91
Gross PPE
68.16
Accumulated Depreciation
-6.25
Properties
0.00
Machinery Furniture Equipment
0.89
Construction In Progress
12.01
Other Properties
52.60
Leases
2.66
Other Non Current Assets
4.60
Total Liabilities Net Minority Interest
70.98
Current Liabilities
25.57
Payables And Accrued Expenses
11.80
Payables
7.86
Accounts Payable
7.86
Current Accrued Expenses
3.94
Employee Benefits
1.53
Pensionand Other Post Retirement Benefit Plans Current
5.62
Current Debt And Capital Lease Obligation
3.13
Current Capital Lease Obligation
3.13
Current Deferred Liabilities
0.00
Current Deferred Revenue
0.00
Other Current Liabilities
5.02
Total Non Current Liabilities Net Minority Interest
45.41
Long Term Debt And Capital Lease Obligation
43.87
Long Term Capital Lease Obligation
43.87
Non Current Pension And Other Postretirement Benefit Plans
1.53
Non Current Deferred Liabilities
0.00
Non Current Deferred Revenue
0.00
Preferred Securities Outside Stock Equity
0.00
Stockholders Equity
271.41
Common Stock Equity
271.41
Capital Stock
0.01
Common Stock
0.01
Preferred Stock
0.00
Share Issued
49.45
Ordinary Shares Number
49.32
Treasury Shares Number
0.12
Additional Paid In Capital
503.70
Retained Earnings
-230.54
Gains Losses Not Affecting Retained Earnings
-1.75
Other Equity Adjustments
-1.75
Total Equity Gross Minority Interest
271.41
Total Capitalization
271.41
Working Capital
250.32
Invested Capital
271.41
Total Debt
47.00
Capital Lease Obligations
47.00
Net Tangible Assets
271.41
Tangible Book Value
271.41
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
-22.80
-154.29%
42.00
+195.88%
-43.80
+52.63%
-92.47
Cash Flow From Continuing Operating Activities
-22.80
-154.29%
42.00
+195.88%
-43.80
+52.63%
-92.47
Net Income From Continuing Operations
-38.63
+46.87%
-72.70
+46.29%
-135.35
-24.75%
-108.50
Depreciation Amortization Depletion
8.36
+2.89%
8.12
+30.52%
6.22
+66.14%
3.75
Depreciation
8.36
+2.89%
8.12
+30.52%
6.22
+66.14%
3.75
Depreciation And Amortization
8.36
+2.89%
8.12
+30.52%
6.22
+66.14%
3.75
Other Non Cash Items
—
—
—
4.81
Stock Based Compensation
18.86
+4.08%
18.13
+8.74%
16.67
+42.91%
11.66
Operating Gains Losses
-0.06
—
0.11
+198.17%
-0.11
Gain Loss On Investment Securities
—
—
0.13
—
Gain Loss On Sale Of PPE
-0.06
0.00
+100.00%
-0.02
+77.98%
-0.11
Change In Working Capital
-9.19
-110.05%
91.40
+26.12%
72.47
+3495.78%
-2.13
Change In Receivables
-11.43
-3541.87%
0.33
-82.50%
1.90
+1114.44%
-0.19
Change In Prepaid Assets
0.60
+138.04%
-1.59
-247.45%
1.08
+150.63%
-2.13
Change In Payables And Accrued Expense
-5.86
-156.11%
10.44
+12.03%
9.31
+3145.64%
0.29
Change In Accrued Expense
7.85
+87.67%
4.18
+17.63%
3.56
+245.00%
1.03
Change In Payable
-13.71
-319.26%
6.25
+8.58%
5.76
+873.92%
-0.74
Change In Account Payable
-13.71
-319.26%
6.25
+8.58%
5.76
+873.92%
-0.74
Change In Other Working Capital
7.49
-90.89%
82.22
+36.63%
60.18
+56340.19%
-0.11
Investing Cash Flow
-101.83
-129.09%
-44.45
-150.06%
88.80
+140.51%
-219.22
Cash Flow From Continuing Investing Activities
-101.83
-129.09%
-44.45
-150.06%
88.80
+140.51%
-219.22
Net PPE Purchase And Sale
-4.70
-17.85%
-3.99
+78.99%
-18.98
-48.25%
-12.80
Purchase Of PPE
-4.70
-17.85%
-3.99
+79.06%
-19.04
-47.48%
-12.91
Sale Of PPE
—
0.00
-100.00%
0.06
-43.12%
0.11
Capital Expenditure
-4.70
-17.85%
-3.99
+79.06%
-19.04
-47.48%
-12.91
Net Investment Purchase And Sale
-97.13
-140.05%
-40.46
-137.54%
107.78
+152.21%
-206.42
Purchase Of Investment
-376.68
-63.52%
-230.36
-123.32%
-103.15
+73.17%
-384.42
Sale Of Investment
279.54
+47.21%
189.90
-9.97%
210.93
+18.50%
178.00
Financing Cash Flow
30.35
-69.31%
98.89
+259.71%
27.49
+34.33%
20.47
Cash Flow From Continuing Financing Activities
30.35
-69.31%
98.89
+259.71%
27.49
+34.33%
20.47
Net Common Stock Issuance
23.89
+7785.48%
0.30
+361.21%
-0.12
-100.58%
20.05
Common Stock Payments
-0.36
+44.31%
-0.64
-452.59%
-0.12
—
Repurchase Of Capital Stock
-0.36
+44.31%
-0.64
-452.59%
-0.12
—
Proceeds From Stock Option Exercised
6.46
-87.48%
51.59
+86.86%
27.61
+3462.32%
0.78
Net Other Financing Charges
—
47.00
+40618.10%
-0.12
+68.13%
-0.36
Changes In Cash
-94.28
-197.76%
96.44
+33.03%
72.49
+124.89%
-291.22
Beginning Cash Position
229.12
+72.68%
132.68
+120.44%
60.19
-82.87%
351.41
End Cash Position
134.84
-41.15%
229.12
+72.68%
132.68
+120.44%
60.19
Free Cash Flow
-27.50
-172.35%
38.01
+160.48%
-62.84
+40.36%
-105.38
Amortization Of Securities
-2.15
+27.24%
-2.95
+24.68%
-3.91
-101.23%
-1.95
Common Stock Issuance
24.25
+2468.86%
0.94
0.00
-100.00%
20.05
Issuance Of Capital Stock
24.25
+2468.86%
0.94
0.00
-100.00%
20.05
Net Preferred Stock Issuance
—
—
—
0.00
Preferred Stock Issuance
—
—
—
0.00
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category